No Detail Found!

Pharmacotherapeutic Evaluation of Covid-19 Patients Suffering from Acute Kidney Injury

Author(s)
Muhammad Osama Yaseen Institute of Pharmaceutical Sciences, University of veterinary and Animal Sciences,Lahore,Pakistan
Misha Yaseen CMH Kharian Medical College,Kharian,Pakistan
Tahir Mehmood Khan Institute of Pharmaceutical Sciences, University of veterinary and Animal Sciences, Lahore, Pakistan. CMH Kharian Medical College, Kharian, Pakistan.
Inayat Rehman Department of Pharmacy, Abdul Wali Khan University,Mardan,Pakistan
Amal K. Suleiman College of Pharmacy, Faculty of Medicine, University of Almaarefa,Riyadh 11597 - Kingdom of,Saudi Arabia
Mirza Rafi Baig Department of Clinical Pharmacy & Pharmacotherapeutics, Dubai Pharmacy College for Girls,Dubai,United Arab Emirates
Ammar A. Jaber Department of Clinical Pharmacy & Pharmacotherapeutics, Dubai Pharmacy College for Girls,Dubai,United Arab Emirates
Ahmed Telb Clemenceau Medical Center,,United Arab Emirates
Farah Nofal Alnafoosi Clemenceau Medical Center,,United Arab Emirates
Abstract
The risk of developing Acute Kidney Injury (AKI) increases manifold during severe acute respiratory syndrome coronavirus-2 (SARS-CoV2) infection. Therefore, the aim of this study is to conduct a comprehensive pharmacotherapeutic evaluation of AKI in COVID-19 patients. A retrospective cohort study was conducted from July to August 2021 among COVID-19 patients admitted to the Institute of Kidney Diseases, Hayatabad Medical Complex hospital in Peshawar Pakistan. The data were extracted based on demographics, diagnosis, laboratory parameters, vital signs, and the treatment used during hospitalization. The association of independent variables was explored using parametric statistics such as regression analysis, one-way ANOVA, and Kruskal-Wallis. Data of N=595 COVID-19 patients with positive PCR tests as per pre-defined criteria were collected. It was observed that fever (n=575 [96.6%]), shortness of breath (n=570 [95.8%]), dry cough (n=449 [75.5%]) and body aches (n=129 [21.7%]) were some of the most common symptoms among the patients. Most of the patients were on a multi-drug regimen during hospitalization. Overall, it was observed that most of the laboratory variables significantly declined in COVID-19 patients with Stage III AKI. Mortality among the patients with AKI was 42% [0.418 [0.269 - 0.632], p=<0.001] as compared to non-AKI patients. There was a significant reduction in mortality by 96% (1.968 [1.277 - 3.033], p-0.002) with the use of intravenous dexamethasone. The prime goal of a clinician is to avoid the use of nephrotoxic drugs during hospitalization and maintain adequate oxygen saturation in order to avoid the development of AKI in COVID-19 patients.
Publication Details
Page(s) 78-87
Published Journal: Archives of Pharmacy Practice, Volume: 13, Issue: 2, Year: 2022

Request the full text from PASTIC

Keywords
COVID-19, SARS-CoV-2, Renal Failure, Covid-19, Kidney disease
0

Citations

0

Downloads

35

Views